Breakthrough: 88% of patients with asthma and nasal polyps achieve dual remission on dupilumab
NCT ID NCT07574294
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study looked at 28 adults with severe asthma and chronic sinusitis with nasal polyps who took dupilumab for 24 months. After two years, 88% had both conditions under control (called dual remission), meaning fewer symptoms, no need for steroid pills, and stable breathing. However, only 32% fully regained their sense of smell, showing that smell recovery is harder to achieve.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda ULSS 2 Marca Trevigiana
Montebelluna, Treviso, 31044, Italy
Conditions
Explore the condition pages connected to this study.